MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414797 | Name: Pazopanib HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pazopanib HCl is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for active clinical trials or closed clinical trials using this agent.

Chemical Structure

Pazopanib HCl
Pazopanib HCl
CAS#635702-64-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 414797

Name: Pazopanib HCl

CAS#: 635702-64-6 (HCl)

Chemical Formula: C21H24ClN7O2S

Exact Mass: 0.0000

Molecular Weight: 473.98

Elemental Analysis: C, 53.22; H, 5.10; Cl, 7.48; N, 20.69; O, 6.75; S, 6.76

Price and Availability

Size Price Availability Quantity
250mg USD 150.00 2 Weeks
500mg USD 225.00 2 Weeks
1g USD 385.00 2 Weeks
2g USD 685.00 2 Weeks
5g USD 1,250.00 2 Weeks
10g USD 2,050.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
635702-64-6 (HCl) 444731-52-6 (free base)
Synonym
Pazopanib hydrochloride; Pazopanib HCl; GW 786034B; GW-786034B; GW786034B
IUPAC/Chemical Name
5-((4-((2,3-Dimethyl-2H-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride
InChi Key
MQHIQUBXFFAOMK-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
SMILES Code
O=S(C1=CC(NC2=NC=CC(N(C3=CC4=NN(C)C(C)=C4C=C3)C)=N2)=CC=C1C)(N)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 473.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
 1: Damassi A, Cremante M, Signori A, Rebuzzi SE, Malgeri A, Napoli MD, Caffo O, Vignani F, Cavo A, Roviello G, Prati V, Tudini M, Atzori F, Messina M, Morelli F, Prati G, Nolè F, Catalano F, Murianni V, Rescigno P, Banna GL, Fornarini G, Buti S. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. Immunotherapy. 2024 Aug 19:1-9. doi: 10.1080/1750743X.2024.2385881. Epub ahead of print. PMID: 39155821. 2: Mobaraki S, Nissen PH, Donskov F, Wozniak A, Van Herck Y, Coosemans L, van Nieuwenhuyse T, Lambrechts D, Bechter O, Baldewijns M, Roussel E, Laenen A, Beuselinck B. Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism. Clin Genitourin Cancer. 2024 Jul 27:102180. doi: 10.1016/j.clgc.2024.102180. Epub ahead of print. PMID: 39155162. 3: Zhou S, Xue J, Yang Q, Zang W, Chen Y, Zhao Y, Gao X. Clinical significance of LIN28A gene polymorphisms and expression in pan-cancer: a meta- analysis and bioinformatic analysis. Nucleosides Nucleotides Nucleic Acids. 2024 Aug 18:1-10. doi: 10.1080/15257770.2024.2393316. Epub ahead of print. PMID: 39154245. 4: Jo JK, Seo SI, Kang M, Chung J, Kwak C, Hong SH, Song C, Park JY, Jeong CW, Choi SH, Kim SH, Chang Hwang E, Lee CH, Lee H. Optimal sequential therapy using tyrosine kinase inhibitors as the first-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study. Asian J Urol. 2024 Jul;11(3):450-459. doi: 10.1016/j.ajur.2022.11.004. Epub 2023 Mar 17. PMID: 39139527; PMCID: PMC11318389. 5: Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris Iii JC, Ryder M, Ho AL, Agulnik M, Wei L, Handley D, Moses C, Jacob R, Wright J, Streicher H, Carson W, Shah MH. Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210/clinem/dgae512. Epub ahead of print. PMID: 39133806. 6: Tan L, Ni Y, Huang Z, Yan J, Wu M, Zhang Z, Zhang F, Wang Z. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review. Future Oncol. 2024 Aug 12:1-19. doi: 10.1080/14796694.2024.2373680. Epub ahead of print. PMID: 39129672. 7: Sarg NH, Hersi FH, Zaher DM, Hamouda AO, Ibrahim SI, El-Seedi HR, Omar HA. Unveiling the therapeutic potential of Taxifolin in Cancer: From molecular mechanisms to immune modulation and synergistic combinations. Phytomedicine. 2024 Aug 3;133:155934. doi: 10.1016/j.phymed.2024.155934. Epub ahead of print. PMID: 39128306. 8: Ma X, Xu J, Ye X, Yang F, Wang Z, Feng J. Early recurrence and extensive retroperitoneal metastasis after surgery for high‑grade mucinous tubular and spindle cell carcinoma: A case report and literature review. Oncol Lett. 2024 Jul 31;28(4):467. doi: 10.3892/ol.2024.14600. PMID: 39119228; PMCID: PMC11306991. 9: Czarnecka AM, Chmiel P, Błoński P, Świtaj T, Rogala P, Falkowski S, Koseła- Paterczyk H, Teterycz P, Kopeć S, Morysiński T, Wągrodzki M, Rutkowski P. Long- term outcomes of sequential chemotherapy in epithelioid sarcoma. J Chemother. 2024 Aug 8:1-12. doi: 10.1080/1120009X.2024.2385261. Epub ahead of print. PMID: 39115147. 10: Matsuoka H, Yoshida KI, Nakai S, Suzuki R, Imura Y, Takami H, Watanabe M, Wakamatsu T, Tamiya H, Outani H, Yagi T, Kakunaga S, Takenaka S. Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report. Mol Clin Oncol. 2024 Jul 29;21(4):69. doi: 10.3892/mco.2024.2767. PMID: 39113850; PMCID: PMC11304161. 11: Edelbach BM, Gospodarev V, Raghavan R, Dye J. Primary intracranial sarcoma, DICER-1 mutant, with hemorrhagic presentation: A case report. Surg Neurol Int. 2024 Jul 26;15:253. doi: 10.25259/SNI_259_2024. PMID: 39108364; PMCID: PMC11302587. 12: Basiri R, Ziaei Moghaddam A, Rikhtegar A, Jafarian AH. Primary Pulmonary Angiosarcoma Found Incidentally in a Complicated Patient: A Rare Case Report. Clin Respir J. 2024 Aug;18(8):e13818. doi: 10.1111/crj.13818. PMID: 39107956; PMCID: PMC11303451. 13: Kumar NN, Sharma S. Stability Indicating UPLC Method Development and Validation for the Quantitative Estimation of Pazopanib in Pure form and Marketed Pharmaceutical Dosage form. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Aug 6;40:e20240018. doi: 10.62958/j.cjap.2024.018. PMID: 39103242. 14: Cao RB, Ge Y, Zhang WX, Lin GH, Kuang BH, Wang BC. The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies. Medicine (Baltimore). 2024 Aug 2;103(31):e38679. doi: 10.1097/MD.0000000000038679. PMID: 39093805; PMCID: PMC11296411. 15: Mustafa D, Ibrahim B, Erten A. Adsorptive removal of anticarcinogen pazopanib from aqueous solutions using activated carbon: isotherm, kinetic and thermodynamic studies. Sci Rep. 2024 Aug 1;14(1):17765. doi: 10.1038/s41598-024-68666-3. PMID: 39085425; PMCID: PMC11291750. 16: Ohno M, Kawaguchi Y, Sugino H, Yoshida A, Takahashi M, Yanagisawa S, Osawa S, Tsuchiya T, Fujita S, Narita Y. Resection and postoperative pazopanib for intraspinal recurrent solitary fibrous tumor: illustrative case. J Neurosurg Case Lessons. 2024 Jul 29;8(5):CASE24217. doi: 10.3171/CASE24217. PMID: 39074397; PMCID: PMC11301598. 17: Jakobsson M, Strambi A, Nilsson F, Arpegård J, Dalén J. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population. Future Oncol. 2024 Jul 26:1-8. doi: 10.1080/14796694.2024.2351352. Epub ahead of print. PMID: 39057291. 18: Lara PN Jr, Villanueva L, Ibanez C, Erman M, Lee JL, Heinrich D, Lipatov ON, Gedye C, Gokmen E, Acevedo A, Semenov A, Park SH, Gafanov RA, Kose F, Jones M, Du X, Munteanu M, Perini R, Choueiri TK, Motzer RJ. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). BMC Cancer. 2024 Jul 25;23(Suppl 1):1253. doi: 10.1186/s12885-023-10971-7. PMID: 39054430; PMCID: PMC11270760. 19: Xu Z, Zhou Z, Yang X, Thakur A, Han N, Li HT, Li LG, Hu J, Li TF, Yan Y. Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer. J Nanobiotechnology. 2024 Jul 20;22(1):429. doi: 10.1186/s12951-024-02694-z. PMID: 39033109; PMCID: PMC11264935. 20: Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Conteduca V, Rebuzzi SE, Beninato T, Venturi G, Doni L, Verzoni E, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, Danesi R. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer. Clin Genitourin Cancer. 2024 Jun 27:102147. doi: 10.1016/j.clgc.2024.102147. Epub ahead of print. PMID: 39030142.